Interface Biologics Appoints Art Rosenthal to Chairman of its Board of Directors

Interface Biologics Inc. (IBI), a privately held commercial stage developer of transformative biomedical-polymer products recently announced the appointment of Arthur L. Rosenthal to Chairman of its Board of Directors.

Read more »